Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CABAZITAXEL Cause Prostatic specific antigen increased? 148 Reports in FDA Database

Prostate Health & Male Vitality — Naturally

ProstaVive: better flow, better sleep, better energy. 180-day guarantee.

Learn More

According to the FDA Adverse Event Reporting System (FAERS), 148 reports of Prostatic specific antigen increased have been filed in association with CABAZITAXEL (Jevtana). This represents 5.8% of all adverse event reports for CABAZITAXEL.

148
Reports of Prostatic specific antigen increased with CABAZITAXEL
5.8%
of all CABAZITAXEL reports
11
Deaths
23
Hospitalizations

How Dangerous Is Prostatic specific antigen increased From CABAZITAXEL?

Of the 148 reports, 11 (7.4%) resulted in death, 23 (15.5%) required hospitalization.

Is Prostatic specific antigen increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CABAZITAXEL. However, 148 reports have been filed with the FAERS database.

What Other Side Effects Does CABAZITAXEL Cause?

Febrile neutropenia (197) Malignant neoplasm progression (172) Fatigue (160) Pyrexia (145) Disease progression (143) Diarrhoea (142) Anaemia (127) Neutropenia (126) Drug ineffective (125) Dyspnoea (113)

What Other Drugs Cause Prostatic specific antigen increased?

ENZALUTAMIDE (3,731) LEUPROLIDE (2,432) ABIRATERONE (1,581) RADIUM RA-223 DICHLORIDE (449) RELUGOLIX (335) BICALUTAMIDE (322) DOCETAXEL (282) APALUTAMIDE (251) DENOSUMAB (220) LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (212)

Which CABAZITAXEL Alternatives Have Lower Prostatic specific antigen increased Risk?

CABAZITAXEL vs CABERGOLINE CABAZITAXEL vs CABOTEGRAVIR CABAZITAXEL vs CABOTEGRAVIR\RILPIVIRINE CABAZITAXEL vs CABOZANTINIB CABAZITAXEL vs CABOZANTINIB S-MALATE

Related Pages

CABAZITAXEL Full Profile All Prostatic specific antigen increased Reports All Drugs Causing Prostatic specific antigen increased CABAZITAXEL Demographics